Rick Wansink (Dept. of Cell Biology) and Roland Brock (Dept. of Biochemistry), both theme Nanomedicine, received a €280,000 grant from the Prinses Beatrix Spierfonds. They will investigate to which degree the required antisense oligonucleotide concentration to correct the defect in myotonic dystrophy depends on the severity of the disease.
In addition, novel methods for targeted delivery will be developed. The results will be crucial for the clinical implementation of oligonucleotide-based therapies.